ST. PAUL, MN – An anticonvulsant drug typically used to control seizures and neuropathic pain may reduce symptoms among those who suffer from restless legs syndrome (RLS), a movement disorder that affects up to 10 percent of the population. A study published in the November 26 issue of Neurology, journal of the American Academy of Neurology, concludes, "Gabapentin may be a potent agent for treatment of even severe RLS, without the disadvantages of long-term complications of previously favored treatments," according to study author Diego Garcia-Borreguero, MD, of the Fundacion Jimenez Díaz in Madrid, Spain.
The above story is based on materials provided by American Academy Of Neurology. Note: Materials may be edited for content and length.
Cite This Page:
American Academy Of Neurology. ""Crossover" Drug Effective For Restless Legs Syndrome." ScienceDaily. ScienceDaily, 26 November 2002. <www.sciencedaily.com/releases/2002/11/021126073328.htm>.
American Academy Of Neurology. (2002, November 26). "Crossover" Drug Effective For Restless Legs Syndrome. ScienceDaily. Retrieved March 8, 2014 from www.sciencedaily.com/releases/2002/11/021126073328.htm
American Academy Of Neurology. ""Crossover" Drug Effective For Restless Legs Syndrome." ScienceDaily. www.sciencedaily.com/releases/2002/11/021126073328.htm (accessed March 8, 2014).